Key Metrics 
Check Before You Invest 
DeciZen 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Viyash Scientific Ltd (VIYASH)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512529 NSE: VIYASH Pharmaceuticals & Drugs | Small Cap | Viyash Scientific Share Price
₹253.15 -3.75 (-1.46%)
As on 23-Jul'26 16:59
Viyash Scientific Ltd (VIYASH)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512529 NSE: VIYASH Pharmaceuticals & Drugs | Small Cap | Viyash Scientific Share Price
₹253.15 -3.75 (-1.46%)
As on 23-Jul'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹11,060 Cr.
Current Price
₹253.2
52-Week Low / High
₹166 / 298
TTM EPS
₹4.1
TTM Sales
₹3,420 Cr.
Book Value per Share
₹61.9
P/E Ratio
62.38
Lower than its 5-year historical median
Industry PE
53.4
Price to Book (P/B)
4.09
Lower than its 5-year historical median
Price to Sales (P/S)
3.23
Higher than its 5-year historical median
EV/EBITDA
16.13
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
9.06%
In line with industry median
Return on Capital Employed (ROCE)
13.10%
Outperforms industry median
Return on Assets (ROA)
5.25%
Operating Profit Margin
19.1%
Net Profit Margin
6.57%
Gross Profit Margin
18.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
13.75%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
69.93%
Net Profit Growth (1 Year)
-
1324.54%
Asset Quality
Promoter Holding
61.31%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹2,618 Cr.
Equity
₹87.4 Cr.
Face Value
₹2
All Time Low / High
₹0.40 / 336.40
Check Before You Invest
Quality
Somewhat GoodValuation
FairCheck Valuation charts
Price Trend
Semi Strong
Is Viyash Scientific Ltd a good quality company?
Viyash Scientific Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Viyash Scientific Ltd performance compare with that of its Peers?
Revenue growth of Viyash Scientific Ltd vs industry peers?
Viyash Scientific Ltd revenue CAGR is 5.64%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Viyash Scientific Ltd?
Promoters hold 61.31% of the Viyash Scientific Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Viyash Scientific Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 6.6% based on the current price.
DeciZen - make an informed investing decision on Viyash Scientific
Decision Maker
Consolidated basis
1. Right Stock
10 Year X-ray Pro
Long Term Prospect
2. Right Price
3. Right Time ⓘ
#Likely Future 5 Year CAGR.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Viyash Scientific Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 1.1% | 4.8% | 9.2% | 12.6% | 16.2% | 7% | -9.7% | -0.6% | 4.8% | 13.1% | - |
| Value Creation Index ⓘ | -0.9 | -0.7 | -0.3 | -0.1 | 0.2 | -0.5 | -1.7 | -1.0 | -0.7 | 0.0 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 3,007 | 3,420 | 3,420 |
| Sales YoY Gr. | - | 24% | 22.6% | 13.5% | 15.5% | 3.8% | 0.6% | -3.6% | 119.5% | 13.8% | - |
| Adj EPS ⓘ | -0.1 | 0.2 | 2.2 | 3 | 4 | 1.5 | -4.5 | -0.5 | 3 | 4.5 | 4.1 |
| YoY Gr. | - | NA | 1042.1% | 36.4% | 35.5% | -63.6% | -408.9% | NA | NA | 52.5% | - |
| BVPS (₹) ⓘ | 39.4 | 25.9 | 27.9 | 27.1 | 29 | 26 | 25.8 | 23.2 | 90 | 61.9 | 61.9 |
| Adj Net Profit ⓘ | -1.6 | 4.7 | 53.6 | 73.4 | 99.6 | 36.4 | -112 | -12.1 | 73.9 | 197 | 177 |
| Cash Flow from Ops. ⓘ | -7.2 | 45.2 | 116 | 115 | 115 | 30.6 | 16.8 | 30.6 | 345 | 323 | - |
| Debt/CF from Ops. ⓘ | -57.8 | 6.7 | 2.8 | 3 | 2 | 10.3 | 23.7 | 14.8 | 1.8 | 1.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 19.6% | 20.2% | 34% | 13.8% | ||||
| Adj EPS ⓘ | NA | 2.3% | NA | 52.5% | ||||
| BVPSⓘ | 5.1% | 16.4% | 34% | -31.2% | ||||
| Share Price | 7% | -2.9% | 42.5% | 38.1% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -0.2 | 0.6 | 7.9 | 10.5 | 14.1 | 5.1 | -16.2 | -1.8 | 4.8 | 7.4 | 6.6 |
| Op. Profit Mgn % ⓘ | 8.5 | 10.3 | 12.8 | 14.9 | 15.7 | 7.8 | 1.7 | 5.6 | 13 | 19.1 | 17.7 |
| Net Profit Mgn % ⓘ | -0.6 | 1.7 | 6 | 7.3 | 8 | 2.8 | -8 | -0.4 | 2.2 | 7.1 | 5.2 |
| Debt to Equity ⓘ | 0.4 | 0.5 | 0.5 | 0.5 | 0.3 | 0.5 | 0.6 | 0.8 | 0.3 | 0.2 | 0.1 |
| Working Cap Days ⓘ | 275 | 246 | 206 | 190 | 179 | 196 | 199 | 208 | 153 | 202 | 106 |
| Cash Conv. Cycle ⓘ | 93 | 89 | 79 | 73 | 80 | 95 | 102 | 106 | 81 | 109 | 56 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 3,007 | 3,420 |
| Operating Expenses ⓘ + | 641 | 765 | 914 | 1,009 | 1,152 | 1,303 | 1,409 | 1,308 | 2,623 | 2,768 |
| Operating Profit ⓘ | 43 | 83 | 125 | 170 | 210 | 109 | 12 | 61 | 384 | 653 |
| Operating Profit Margin (%) | 6.3% | 9.8% | 12.0% | 14.4% | 15.4% | 7.7% | 0.8% | 4.5% | 12.8% | 19.1% |
| Other Income ⓘ + | 11 | 17 | 9 | 10 | 10 | 11 | 6 | 11 | 36 | 44 |
| Interest ⓘ | 28 | 33 | 33 | 36 | 24 | 16 | 36 | 48 | 86 | 69 |
| Depreciation ⓘ | 40 | 41 | 42 | 51 | 51 | 52 | 56 | 62 | 239 | 234 |
| Profit Before Tax ⓘ | -14 | 24 | 59 | 94 | 137 | 53 | -138 | -55 | 13 | 349 |
| Tax ⓘ | -1 | 13 | 2 | 12 | 32 | 8 | -16 | -25 | -3 | 124 |
| Profit After Tax | -14 | 10 | 57 | 82 | 104 | 45 | -122 | -30 | 16 | 225 |
| PAT Margin (%) | -2.0% | 1.2% | 5.5% | 7.0% | 7.7% | 3.2% | -8.6% | -2.2% | 0.5% | 6.6% |
| Adjusted EPS (₹) | -0.6 | 17.3 | 2.0 | 2.8 | 3.8 | 1.7 | -4.9 | -1.4 | 0.9 | 4.1 |
| Dividend Payout Ratio (%) | 0% | 1.20% | 10.20% | 0% | 13% | 0% | 0% | 0% | 0% | 0% |
Valuation of Viyash Scientific - Consolidated
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 961 | 630 | 688 | 673 | 720 | 645 | 642 | 579 | 2,252 | 2,705 | |
| Debt + | 360 | 256 | 275 | 297 | 197 | 282 | 332 | 389 | 557 | 424 | |
| Minority Interest | 17 | 37 | 40 | 45 | 49 | 48 | 50 | 56 | 133 | 204 | |
| Trade Payables | 203 | 160 | 209 | 220 | 227 | 258 | 244 | 251 | 489 | 597 | |
| Others Liabilities ⓘ | 362 | 259 | 189 | 228 | 251 | 254 | 214 | 256 | 588 | 615 | |
| Total Liabilities ⓘ | 1,904 | 1,343 | 1,402 | 1,463 | 1,443 | 1,487 | 1,484 | 1,531 | 4,020 | 4,545 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 | 2,103 | 2,103 | |
| CWIP ⓘ | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 16 | 43 | 70 | |
| Investments ⓘ | 428 | 239 | 180 | 171 | 83 | 38 | 0 | 4 | 0 | 0 | |
| Inventories | 161 | 159 | 200 | 219 | 264 | 348 | 346 | 346 | 682 | 803 | |
| Trade Receivables | 255 | 258 | 278 | 319 | 346 | 329 | 341 | 336 | 806 | 1,045 | |
| Cash Equivalents | 47 | 42 | 72 | 76 | 56 | 59 | 42 | 70 | 157 | 270 | |
| Others Assets ⓘ | 296 | 150 | 151 | 88 | 127 | 136 | 94 | 168 | 227 | 253 | |
| Total Assets ⓘ | 1,904 | 1,343 | 1,402 | 1,463 | 1,443 | 1,487 | 1,484 | 1,531 | 4,020 | 4,545 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -7 | 45 | 116 | 115 | 115 | 31 | 17 | 31 | 345 | 323 |
| Cash Flow From Investing Activity ⓘ + | -116 | 7 | -68 | -72 | 10 | -96 | -65 | -6 | -447 | -84 |
| Cash Flow From Financing Activity ⓘ + | 147 | -57 | -20 | -43 | -139 | 67 | 32 | -1 | 87 | -123 |
| Net Cash Flow ⓘ | 24 | -5 | 28 | 0 | -14 | 2 | -16 | 23 | -15 | 115 |
Financial Ratio
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -1.47 | 1.28 | 8.63 | 12.06 | 15 | 6.56 | -18.95 | -4.85 | 1.11 | 9.06 |
| ROCE (%) | 1.05 | 4.84 | 9.24 | 12.59 | 16.24 | 7.01 | -9.71 | -0.6 | 4.8 | 13.1 |
| Asset Turnover Ratio | 0.4 | 0.52 | 0.77 | 0.84 | 0.96 | 0.98 | 0.98 | 0.94 | 1.08 | 0.8 |
| PAT to CFO Conversion(x) | N/A | 4.5 | 2.04 | 1.4 | 1.11 | 0.69 | N/A | N/A | 21.56 | 1.44 |
| Working Capital Days | ||||||||||
| Receivable Days | 118.40 | 110.20 | 92.50 | 90.50 | 87.40 | 85.50 | 84.10 | 87.50 | 69.30 | 98.80 |
| Inventory Days | 78.40 | 68.60 | 61.90 | 63.60 | 63.60 | 77.50 | 87.10 | 89.50 | 62.40 | 79.30 |
| Payable Days | 177.50 | 143.60 | 124.30 | 129.60 | 117.50 | 111.60 | 110 | 119 | 91.90 | 126.90 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Viyash Scientific Ltd FAQs
The current trading price of Viyash Scientific on 23-Jul-2026 16:59 is ₹253.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Jul-2026 the market cap of Viyash Scientific stood at ₹11,059.5 Cr
The latest P/E ratio of Viyash Scientific as of 22-Jul-2026 is 145.8.
The latest P/B ratio of Viyash Scientific as of 22-Jul-2026 is 3.70.
The 52-week high of Viyash Scientific is ₹297.9 and the 52-week low is ₹166.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Viyash Scientific is ₹1,382 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Viyash Scientific Ltd is a average quality company.
The key valuation ratios of Viyash Scientific Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Viyash Scientific Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Viyash Scientific Ltd
P I Drugs & Pharmaceuticals Ltd. established in 1991 is a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.
P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the formulation belonging to anthelmintic & anti-parasitic segment.
In September 2007 PI Drugs purchased the pharma division of Transchem Limited.
The company is engaged in the business of human health & animal health and enjoys high Image for distribution in domestic as well as international markets.
They have a specialized and dedicated WHO - GMP accredited manufacturing plant for the manufacture of API's. It exports to all major markets like Europe, South America, Australia, Asia and Africa.
They started with the introduction of Albendazole and has developed core competency in chemistry of Benzimadazole in very short time.
Product range of the company includes:
Human / Veterinary Formulations
- Diminazene Diaceturate
- Toldimfos Sodium
- Quinapyramine
- Triclabendazole
- Albendazole
- Fenbendazole
- Oxyclozanide
- Niclosamide
- Frusemide
- Mebendazole
Honey Bee Medicine
- Pizitol®
- Apistonic®
- Transprim®
Human / Veterinary API's
Veterinary API’s
- Albendazole USP/EP/BP
- Fenbendazole BP/ EP/BP VET
- Oxfendazole EP/BP VET
- Mebendazole USP/EP/BP/POLY 'C'
Human API's
- Pentamidine Isethionate
- Ramipril EP / BP
- Frusemide USP / EP / BE
- Cetrizine DI HCL BP / EP
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
